Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02018848
Other study ID # HU-ATP-OCD-2013
Secondary ID
Status Completed
Phase N/A
First received November 28, 2013
Last updated November 11, 2014
Start date October 2013
Est. completion date July 2014

Study information

Verified date November 2014
Source Humboldt-Universität zu Berlin
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

The goal of this study is to investigate an attention training program for participants with Obsessive-Compulsive Disorder. The attention training consists of a modified dot probe task with picture stimuli related to washing and checking paired with neutral pictures.

Participants are randomly assigned to an experimental and a placebo-control group. After a minimum of 4 weeks of attention training we expect to find differences between participants of the experimental and the control group in terms of attention bias, OCD symptoms, anxiety and depression.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- diagnosis of primary OCD according to OCI-R self report (cut-off >=18)

Exclusion Criteria:

- suicidal

- substance abuse or addiction

- psychotic symptoms

- visual impairment if not compensated with optical aid

Current treatment is not an exclusion criterion, but data on treatment status (current psycho- or pharmacotherapy for OCD) will enter our statistical analyses.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Attention Training Program


Locations

Country Name City State
Germany Humboldt-Universität zu Berlin Berlin

Sponsors (1)

Lead Sponsor Collaborator
Humboldt-Universität zu Berlin

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Beck Anxiety Inventory (BAI) T1 The BAI measures severity of anxiety symptoms. pre-treatment, estimated: between day 1 and day 7 after enrolment (no time limit set, all further steps relative to exact time point of T1 questionnaires) No
Other Beck Anxiety Inventory (BAI) T2 The BAI measures severity of anxiety symptoms. post-treatment, between day 1 and 6 after T2 Bias Assessment (time limit set) No
Other Beck Anxiety Inventory (BAI) T3 The BAI measures severity of anxiety symptoms. follow-up, between day 27 and 50 after T2 questionnaires (time limit set) No
Other Beck Depression Inventory II (BDI-II) T1 The BDI measures severity of depressive symptoms. pre-treatment, estimated: between day 1 and day 7 after enrolment (no time limit set, all further steps relative to exact time point of T1 questionnaires) No
Other Beck Depression Inventory II (BDI-II) T2 The BDI measures severity of depressive symptoms. post-treatment, between day 1 and 6 after T2 Bias Assessment (time limit set) No
Other Beck Depression Inventory II (BDI-II) T3 The BDI measures severity of depressive symptoms. follow-up, between day 27 and 50 after T2 questionnaires (time limit set) No
Other Attention bias towards OCD-relevant stimuli at T1 measured with a dot-probe task. Attention bias is measured using a dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented briefly on a computer screen. Next, a probe randomly appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard.
Attention bias is calculated as the mean difference in reaction times between trials in which the probe appears at the OCD-relevant location vs. trials in which it appears at the neutral location. The bias assessment session is masked as first training sessions in both groups.
after T1 questionnaires and pre-treatment, estimated: between day 1 and 3 after T1 questionnaires (no time limit set) No
Other Attention bias towards OCD-relevant stimuli at T2 measured with a dot-probe task. Attention bias is measured using a dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented briefly on a computer screen. Next, a probe randomly appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard.
Attention bias is calculated as the mean difference in reaction times between trials in which the probe appears at the OCD-relevant location vs. trials in which it appears at the neutral location.
post-treatment, after a minimum of 8 training sessions over a time of 4 weeks, estimated: between day 1 and 4 after last training session (no time limit set) No
Primary Yale-Brown Obsessive-Compulsive Scale Self-Report Scale (Y-BOCS-SRS) T1 The Y-BOCS-SRS measures severity of OCD symptoms. pre-treatment, estimated: between day 1 and day 7 after enrolment (no time limit set) No
Primary Yale-Brown Obsessive-Compulsive Scale Self-Report Scale (Y-BOCS-SRS) T2 The Y-BOCS-SRS measures severity of OCD symptoms. post-treatment, between day 1 and 6 after T2 Bias Assessment (time limit set) No
Primary Yale-Brown Obsessive-Compulsive Scale Self-Report Scale (Y-BOCS-SRS) T3 The Y-BOCS-SRS measures severity of OCD symptoms. follow-up, between day 27 and 50 after T2 questionnaires (time limit set) No
Secondary Obsessive-Compulsive Inventory-Revised (OCI-R) T1 The OCI-R measures severity of OCD symptoms. pre-treatment, estimated: between day 1 and day 7 after enrolment (no time limit set) No
Secondary Obsessive-Compulsive Inventory-Revised (OCI-R) T2 The OCI-R measures severity of OCD symptoms. post-treatment, between day 1 and 6 after T2 Bias Assessment (time limit set) No
Secondary Obsessive-Compulsive Inventory-Revised (OCI-R) T3 The OCI-R measures severity of OCD symptoms. follow-up, between day 27 and 50 after T2 questionnaires (time limit set) No
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3

External Links